PMEF
ACAD icon

Point72 Middle East FZE’s Acadia Pharmaceuticals ACAD Stock Holding History

Point72 Middle East FZE’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,356
Closed -$607K – 1395
2023
Q2 		$607K Buy
+25,356
New +$564K 0.02% 723

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Point72 Middle East FZE's ACAD Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Acadia Pharmaceuticals (ACAD) in Q3 2023, closing a stake of 25,356 shares — an estimated $607K sold.

Point72 Middle East FZE first reported a position in ACAD in Q2 2023 and held it in 1 quarter. The position peaked at $607K in Q2 2023. 248 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Acadia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 25,356 Acadia Pharmaceuticals shares in Q3 2023, an estimated $607K.
  • Point72 Middle East FZE first reported a position in Acadia Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Acadia Pharmaceuticals position peaked at $607K in Q2 2023.
  • 248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.